Erfan Bashar
Back to Autoimmune Encephalitis

Autoimmune Encephalitis — Treatment

Updated:
~3 min read
Last medically reviewed:
On this pageTable of contents

Educational scope notice: This is a study note for medical students, not medical advice, diagnosis, or treatment guidance. Clinical management should follow local protocols and current guidelines. Drug dosing below is intentionally omitted; exact regimens, monitoring, and prophylaxis follow local protocols.

The governing principle is to start immunotherapy on clinical suspicion once infection has been reasonably excluded, without waiting for definitive antibody results. Delay worsens outcomes, and the response itself is diagnostically informative: a clear objective improvement supports the autoimmune diagnosis, while no response should prompt reconsideration.

First-line therapy: steroids, IVIG, and plasma exchange

First-line treatment combines rapidly acting, relatively low-risk options, often together in moderate to severe disease:

  • High-dose intravenous methylprednisolone given as pulses suppresses lymphocyte activation, cytokine production, and barrier permeability. It can act quickly but brings hyperglycaemia, hypertension, and psychiatric effects.
  • Intravenous immunoglobulin (IVIG) provides a large pool of normal immunoglobulin that competes with pathogenic autoantibodies and modulates Fc-receptor and anti-idiotypic networks.
  • Plasma exchange physically removes circulating antibodies and immune complexes over several sessions. It suits antibody-mediated disease well but needs central access, and it also removes therapeutic antibodies, so sessions scheduled shortly after IVIG or rituximab need careful timing, with steroids covering the gap.

Many centres open with steroids plus IVIG and add plasma exchange for severe disease or when the first combination fails. Exact pulse doses, course lengths, and taper schedules vary between protocols and are set locally.

Escalation: rituximab and cyclophosphamide

Expert practice advises escalation when there is no meaningful improvement roughly 10–14 days after first-line therapy begins. That window reflects cohort experience and expert consensus rather than randomised trials:

  • Rituximab, an anti-CD20 monoclonal antibody, depletes B cells and thereby reduces autoantibody production. It is the less toxic of the two and the usual first choice at escalation.
  • Cyclophosphamide, an alkylating agent suppressing B- and T-cell activity, is more potent and more toxic, with marrow suppression, bladder toxicity, infertility, and second malignancy among its risks. It is reserved for severe or refractory disease.

First-line measures typically continue while second-line agents take effect, then taper once stability is confirmed.

Maintenance and refractory options

Some patients need prolonged immunosuppression against relapse. Azathioprine (a purine synthesis inhibitor) and mycophenolate mofetil (a lymphocyte guanosine synthesis inhibitor) serve as steroid-sparing maintenance, alongside low-dose oral prednisone tapered slowly once the disease is stable.

Refractory disease has been approached with cytokine and plasma-cell-directed agents including the anti-IL-6 receptor antibody tocilizumab, the proteasome inhibitor bortezomib (which reaches antibody-producing plasma cells that rituximab misses), the anti-CD19 antibody inebilizumab, and the IL-1 receptor antagonist anakinra. Choice depends on the antibody syndrome, severity, prior response, and toxicity.

Patients with surface-directed antibodies often need a shorter course once the pathogenic antibody clears, while intracellular-antibody disease with T-cell-mediated injury tends to run a more refractory course needing longer suppression. These are tendencies, not guarantees for any individual.

Paraneoplastic disease: treat the tumour too

When the encephalitis is tumour-driven, oncological treatment runs alongside immunotherapy, because removing the antigen source is part of stopping the process. Immunotherapy starts while the cancer workup proceeds rather than after it. If a tumour is found, standard cancer treatment continues in parallel; if screening is initially negative but suspicion stays high, surveillance repeats at intervals (see the diagnosis note), since the tumour can become detectable later.

What shapes the outcome

Earlier treatment, a surface-directed antibody, and absence of an underlying malignancy each favour recovery; intracellular antibodies, paraneoplastic disease, and delayed therapy point the other way. Even with prompt care the illness can be fatal, which is why the start-early principle dominates every guideline.

Evidence anchors

Suggest a correction